Although some investigations demonstrated that HMGB1 inhibition has encouraging outcomes in the context of diabetes-associated pathologies [[44], [45], [46], [47]], to this day, no in vivo study has established a direct causal link between systemic HMGB1 knockdown and hyperglycemia. This evidence concerns the gene HMGB1 and diabetes mellitus.